50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:CERS

Cerus - CERS Stock Forecast, Price & News

$3.43
-0.04 (-1.15%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.39
$3.59
50-Day Range
$3.43
$5.83
52-Week Range
$3.39
$8.06
Volume
1.04 million shs
Average Volume
1.78 million shs
Market Capitalization
$607.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Cerus MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Cerus in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$51,200 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

1043rd out of 1,071 stocks

Surgical & Medical Instruments Industry

103rd out of 106 stocks

CERS stock logo

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

Cerus (NASDAQ:CERS) Hits New 12-Month Low at $3.66
Cerus Corporation (CERS)
Cerus (CERS) Q2 2022 Earnings Call Transcript
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings
11/02/2021
Today
9/27/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
631
Year Founded
1991

Profitability

Net Income
$-54,380,000.00
Pretax Margin
-27.16%

Debt

Sales & Book Value

Annual Sales
$130.86 million
Book Value
$0.50 per share

Miscellaneous

Free Float
164,109,000
Market Cap
$607.42 million
Optionable
Optionable
Beta
1.14

Social Links


Key Executives

  • Mr. William M. Greenman (Age 55)
    Pres, CEO & Director
    Comp: $1.25M
  • Dr. Laurence M. CorashDr. Laurence M. Corash (Age 78)
    Co-Founder & Chief Scientific Officer
    Comp: $697.77k
  • Mr. Kevin D. Green (Age 50)
    VP of Fin. & CFO
    Comp: $698.15k
  • Mr. Vivek K. JayaramanMr. Vivek K. Jayaraman (Age 47)
    Chief Operating Officer
    Comp: $845.3k
  • Dr. Richard J. Benjamin (Age 62)
    Chief Medical Officer
    Comp: $718.64k
  • Ms. Lori L. Roll
    VP of Admin. & Corp. Sec.
  • Mr. Matthew M. Notarianni
    Sr. Director of Investor Relations
  • Ms. Chrystal N. MenardMs. Chrystal N. Menard (Age 51)
    Chief Legal Officer & Gen. Counsel
  • Lainie Corten
    VP of Global Marketing
  • Ms. Carol M. MooreMs. Carol M. Moore (Age 72)
    Sr. VP of Regulatory Affairs, Quality & Clinical













CERS Stock - Frequently Asked Questions

How have CERS shares performed in 2022?

Cerus' stock was trading at $6.81 at the beginning of 2022. Since then, CERS shares have decreased by 49.5% and is now trading at $3.44.
View the best growth stocks for 2022 here
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The biotechnology company had revenue of $36.13 million for the quarter, compared to analysts' expectations of $31.60 million. Cerus had a negative trailing twelve-month return on equity of 52.16% and a negative net margin of 27.34%. During the same quarter last year, the business posted ($0.08) EPS.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $176.65 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (9.67%), Sumitomo Mitsui Trust Holdings Inc. (5.82%), Nikko Asset Management Americas Inc. (5.82%), Primecap Management Co. CA (5.23%), State Street Corp (2.53%) and Assenagon Asset Management S.A. (1.69%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends
.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $3.44.

How much money does Cerus make?

Cerus (NASDAQ:CERS) has a market capitalization of $609.19 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Cerus have?

The company employs 631 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.